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Asthma is a chronic inflammatory disease of the lung and its pathophysiology is initiated by mast cell 
activation in response to the antigen binding to IgE receptor as well as by TH2 cell activation. Mast cells 
are well established effector cells in asthma where they exacerbate the inflammatory response, playing a 
key role in early phase, degranulating and increasing histamine. Human mast cells possess high affinity 
IgE receptors and are ubiquitous but predominantly localized in mucosal and connective tissue and are 
distributed along blood vessels. There are two types of mast cells: connective tissue mast cells (TC) and 
mucosal mast cells (T mast cells). TC mast cells contain more heparin, whereas T mast cells contain 
more chondroitin sulfate. In asthma, mast cell activation can trigger degranulation, releasing secretory 
granule complex and preformed mediators, such as histamine and proteases, along with the synthesis of 
leukotrines and prostaglandins, and induction of cytokines and chemokines. Leukotrine inhibitors and 
omalizumab, which inhibits IgE, both relieve the asthma exacerbation when administered to humans 
and permit to reduce the use of other drugs. The release of cytokines by mast cells, such as TNF-alpha, 
IL-1, IL-6 and IL-33, participate in the pathogenesis of asthma. Stress worsens asthma, and this effect 
is also mediated by mast cell activation through the release of cytokines. Administration of IL-33 in 
experimental animals provokes pathological effects in the mucosal tissues and augments antibody IgE 
and IgA in blood vessels. Here, we report the impact of mast cell biology in asthma pathogenesis.
ASTHMA AND MAST CELL BIOLOGY
S.K. KRITAS1, A. SAGGINI2, G. CERULLI3, A. SPEZIALI3, A. CARAFFA4, P. ANTINOLFI4,
A. PANTALONE5, M. ROSATI6, M. TEI3, R. SAGGINI7 and P. CONTI8
1Department of Microbiology and Infectious Diseases, School of Veterinary Medicine, Aristotle 
University of Thessaloniki, Macedonia, Greece; 2Department of Dermatology, University of 
Rome Tor Vergata, Rome, Italy; 3Nicola’s Foundation, Onlus, Arezzo, Italy; 4Orthopedic Division, 
University of Perugia, Perugia, Italy; 5Orthopedic Division, University of Chieti-Pescara, Chieti, 
Italy; 6Gynecology Clinic, Pescara Hospital, Pescara, Italy; 7Department of Neurosciences and 
Imaging, Faculty of Medicine and Surgery, G. d’Annunzio University Chieti-Pescara, Chieti, Italy; 
8Immunology Division, Medical School, University of Chieti-Pescara, Chieti, Italy
Received  May 30, 2014 – Accepted July 10, 2014
